Cargando…
Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
Cabazitaxel (CBZ) is approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). However, its efficacy against CRPC is limited, and there are no effective treatments for CBZ-resistant CRPC. This study explored the optimal treatment for CRPC in the post-cabazitaxel...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593019/ https://www.ncbi.nlm.nih.gov/pubmed/34782700 http://dx.doi.org/10.1038/s41598-021-01697-2 |